The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 1—Key Points of the Fifth Edition and Summary of Imaging Findings on Adult‐Type Diffuse Gliomas

Qualitative and Quantitative Magnetic Resonance Imaging Phenotypes May Predict CDKN2A/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytomas: A Multicenter Study

(2023) Yae Won Park et al.   KOREAN JOURNAL OF RADIOLOGY

Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas

(2022) Daniel J. Brat et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Gyriform infiltration as imaging biomarker for molecular glioblastomas

(2022) Emmanuel Mesny et al.   JOURNAL OF NEURO-ONCOLOGY

Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States

(2022) J Bryan Iorgulescu et al.   NEURO-ONCOLOGY

Sex as a prognostic factor in adult-type diffuse gliomas: an integrated clinical and molecular analysis according to the 2021 WHO classification

(2022) Minjae Kim et al.   JOURNAL OF NEURO-ONCOLOGY

Telomerase reverse transcriptase promoter mutation and histologic grade in IDH wild-type histological lower-grade gliomas: The value of perfusion-weighted image, diffusion-weighted image, and 18F-FDG-PET

(2022) Satoshi Ikeda et al.   EUROPEAN JOURNAL OF RADIOLOGY

The T2-FLAIR mismatch sign as a predictor of IDH-mutant, 1p/19q-noncodeleted lower-grade gliomas: a systematic review and diagnostic meta-analysis

(2021) Sang Ik Park et al.   EUROPEAN RADIOLOGY

MRI Features May Predict Molecular Features of Glioblastoma in Isocitrate Dehydrogenase Wild-Type Lower-Grade Gliomas

(2021) C.J. Park et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Magnetic Resonance Imaging Parameters for Noninvasive Prediction of Epidermal Growth Factor Receptor Amplification in Isocitrate Dehydrogenase-Wild-Type Lower-Grade Gliomas: A Multicenter Study

(2021) Yae Won Park et al.   NEUROSURGERY

Reproducible imaging-based prediction of molecular subtype and risk stratification of gliomas across different experience levels using a structured reporting system

(2021) Yeo Kyung Nam et al.   EUROPEAN RADIOLOGY

Identification of magnetic resonance imaging features for the prediction of molecular profiles of newly diagnosed glioblastoma

(2021) Sung Soo Ahn et al.   JOURNAL OF NEURO-ONCOLOGY

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

(2021) David N Louis et al.   NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018

(2021) Quinn T Ostrom et al.   NEURO-ONCOLOGY

cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas

(2020) Daniel J. Brat et al.   ACTA NEUROPATHOLOGICA

‘Real world’ use of a highly reliable imaging sign: ‘T2-FLAIR mismatch’ for identification of IDH mutant astrocytomas

(2020) Rajan Jain et al.   NEURO-ONCOLOGY

cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading

(2020) David N. Louis et al.   BRAIN PATHOLOGY

Molecular characteristics and clinical features of multifocal glioblastoma

(2020) Antonio Dono et al.   JOURNAL OF NEURO-ONCOLOGY

cIMPACT‐NOW update 7: advancing the molecular classification of ependymal tumors

(2020) David W. Ellison et al.   BRAIN PATHOLOGY

Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas

(2020) Yae Won Park et al.   EUROPEAN RADIOLOGY

Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach

(2019) Anna Latysheva et al.   NEURORADIOLOGY

cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation

(2019) David W. Ellison et al.   ACTA NEUROPATHOLOGICA

Prediction of IDH genotype in gliomas with dynamic susceptibility contrast perfusion MR imaging using an explainable recurrent neural network

(2019) Kyu Sung Choi et al.   NEURO-ONCOLOGY

IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations

(2019) Rui Ryan Yang et al.   BRAIN PATHOLOGY

cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant

(2018) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Novel, improved grading system(s) for IDH-mutant astrocytic gliomas

(2018) Mitsuaki Shirahata et al.   ACTA NEUROPATHOLOGICA

cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC)

(2018) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations

(2018) Annekathrin Reinhardt et al.   ACTA NEUROPATHOLOGICA

Whole-Tumor Histogram and Texture Analyses of DTI for Evaluation ofIDH1-Mutation and 1p/19q-Codeletion Status in World Health Organization Grade II Gliomas

(2018) Y.W. Park et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

MRI Features Can Predict 1p/19q Status in Intracranial Gliomas

(2018) A. Lasocki et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis

(2018) Chong Hyun Suh et al.   EUROPEAN RADIOLOGY

2-hydroxyglutarate MR Spectroscopy for Prediction of Isocitrate Dehydrogenase Mutant Glioma: A Systemic Review and Meta-analysis using Individual Patient Data

(2018) Chong Hyun Suh et al.   NEURO-ONCOLOGY

cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”

(2018) Daniel J. Brat et al.   ACTA NEUROPATHOLOGICA

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015

(2018) Quinn T Ostrom et al.   NEURO-ONCOLOGY

Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups

(2018) Tareq A. Juratli et al.   JOURNAL OF NEURO-ONCOLOGY

Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas

(2017) Khalil Abou-El-Ardat et al.   NEURO-ONCOLOGY

MRI features predict survival and molecular markers in diffuse lower-grade gliomas

(2017) Hao Zhou et al.   NEURO-ONCOLOGY

Oligodendrogliomas in pediatric and adult patients: an outcome-based study from the Surveillance, Epidemiology, and End Result database

(2017) Christine SM Lau et al.   Cancer Management and Research

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system

(2016) Haihui Jiang et al.   Oncotarget

IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy

(2014) Giuseppe Minniti et al.   JOURNAL OF NEURO-ONCOLOGY

IDHMutation in Glioma

(2014) Zorbey Turkalp et al.   JAMA Neurology

Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

(2013) W. Wick et al.   NEUROLOGY

IDH1 Mutations Are Early Events in the Development of Astrocytomas and Oligodendrogliomas

(2009) Takuya Watanabe et al.   AMERICAN JOURNAL OF PATHOLOGY